Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined effect of vibegron and imidafenacin for overactive bladder
jRCTs031190106Completed
- Sponsor
- Kyorin Pharmaceutical
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in overactive bladder (OAB) comparing Vibegron monotherapy with Vibegron + imidafenacin combination (2 arms). Primary endpoint: Change in OABSS total score from baseline to week 8. Started Nov 2019; status: completed.
02
Drugs
vibegronimidafenacin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on jRCTs031190106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190106.